Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

"Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly has spent recent years reintroducing itself to the public via a series of corporate campaigns, and its latest push goes a step further.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, including with its GLP-1 medications.

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity ...

Has Eli Lilly's stock indeed peaked, and could this be the start of a much broader sell-off, or is now a potentially good time to add the healthcare giant to your portfolio?

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...

Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...